We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Potential Noninvasive Biomarker of EoE Disease Activity Identified

By LabMedica International staff writers
Posted on 24 May 2016
Researchers have identified a potential blood-based marker of disease activity for the severe and often painful food allergic disease eosinophilic esophagitis (EoE) – possibly leading to a blood test, which could spare EoE patients, often children, the discomfort and risk of the currently used invasive endoscopic monitoring procedures.

Researchers at the Cincinnati Center for Eosinophilic Disorders (CCED) of Cincinnati Children’s Hospital Medical Center (Cincinnati, OH, USA) led the study. More...
“Adults and children with EoE can be on highly restricted diets of formula alone or only a few foods,” said Patricia C. Fulkerson, MD, PhD, senior study author, “One of the major obstacles to families participating in studies to introduce foods back into the child’s diet is the need for endoscopy after each food is tried to see whether or not it triggers disease activity.”

The disease activity of EoE is currently monitored using peak esophageal eosinophil count, which requires endoscopy to collect esophageal tissue biopsies. People with EoE, a lifelong disease, must continue monitoring disease activity, even after effective treatment with restricted diets or steroids. Treatment changes, such as reintroducing a single food, require additional endoscopic exams to assess for disease flare-ups.

Prior research has demonstrated that testing blood of EoE patients is not a clinically useful indication of active disease because eosinophil levels in blood do not correlate well with levels in the esophagus. This led the team to investigate a precursor cell to eosinophils, a lineage-committed eosinophil progenitor (EoP), as a potential marker. They found elevated EoP levels in the blood of pediatric patients with active EoE disease, suggesting a promising, blood-based marker.

The authors emphasize that additional research is needed to validate the marker before routine clinical use. “This clinical study is the first to investigate EoP levels in patients with EoE and identifies a potential new noninvasive biomarker,” said study author Vincent A. Mukkada, MD, physician at Cincinnati Children’s and CCED member, “This work is an essential step toward improving outcomes for patients with EoE. It will be followed by repeated testing of more patients and with sequential measurements of EoP levels in the same patient during different disease states.”

Allergic diseases have been on the rise over the past 20 years. The CCED team has previously reported that incidence of EoE is estimated at 1 of 1,000 people. Their research has also shown that EoE is caused by a combination of genetic and environmental factors, and is primarily mediated by an immunologic response to foods. The hallmark of EoE is swelling and inflammation in the esophagus, accompanied by high levels of eosinophils.

The study, by Morris DW et al, was published May 16, 2016, in the Journal of Allergy and Clinical Immunology.

Related Links:
Cincinnati Children’s Hospital Medical Center


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.